FDA New Year’s Resolution: Guidances On Payor Communications, Biosimilarity
Executive Summary
Agency expects to issue 101 guidances in 2017, including those on REMS assessment, refusal to file NDA and BLA submissions, and amendments to ANDAs.
You may also be interested in...
Trump Order Reducing Regulation Might Imperil FDA Good Guidance Practices
Executive order mandating two existing regulations be eliminated for every new one issued includes guidances, raising questions about how FDA will communicate with industry going forward.
Biosimilar Guidances Could Be Left Out In Cold By White House Regulatory Freeze
Trump Administration memo could further delay some US FDA guidance documents already past due under the FDA Safety and Innovation Act; attorneys predict uncertainty about, but no immediate impact on, biosimilar and communications draft guidances released in last few weeks of the Obama Administration.
Biosimilar Guidances Could Be Left Out In Cold By White House Regulatory Freeze
Trump Administration memo could further delay some US FDA guidance documents already past due under the FDA Safety and Innovation Act; attorneys predict uncertainty about, but no immediate impact on, biosimilar and communications draft guidances released in last few weeks of the Obama Administration.